Trump Pick For Health and Human Services Lied During Testimony
Donald Trump’s pick for Secretary of Health and Human Services lied about receiving an exclusive deal to purchase stock from an Australian pharmaceutical company, the Wall Street Journal reported Monday.
The Wall Street Journal report directly contradicts Tom Price’s testimony during his confirmation hearings when discussing the purchase of the discounted shares of Innate Immunotherapeutics. Price had said that the share “were available to every single individual that was an investor at the time.”
But according to the CEO of Innate Immuno CEO Simon Wilkinson those investors who had previously participated in a private placement had been invited to “make friends and family aware of the opportunity” to buy discounted shares.
The Wall Stree Journal reported the exclusive discount in an interview with Rep. Chris Collins, who owns a 17 percent stake in the company and who made Price aware of the stock opportunity.
Tom Price was one of just six “friends and family” of investors previously involved in a private placement who were offered the special discounted rates, according to the Journal.
And according to the Wall Street Journal, after that initial investment, Price invested larger amounts in Innate Immuno stock at discounted rates. On two separate occasions, Price invested a net of $50,000-$100,000, according to disclosure forms.
